• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异源 SCB-2019 疫苗对科兴疫苗 primed 成年人对奥密克戎 SARS-CoV-2 变异株中和滴度的增强作用优于同源加强针。

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults.

机构信息

Department of Physiology, Philippine General Hospital, University of the Philippines, Manila, Philippines.

Las Pinas Doctors Hospital, Las Pinas City, Philippines.

出版信息

J Infect Dis. 2023 Nov 2;228(9):1253-1262. doi: 10.1093/infdis/jiad262.

DOI:10.1093/infdis/jiad262
PMID:37439701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10629704/
Abstract

BACKGROUND

We compared homologous and heterologous boosting in adults in the Philippines primed with 2 or 3 doses of CoronaVac, with recombinant protein vaccine, SCB-2019.

METHODS

CoronaVac-immunized adults (18-72 years) received a homologous or heterologous full or half dose SCB-2019 booster. We assessed all neutralizing antibody (NAb) responses against prototype SARS-CoV-2 after 15 days and NAb against SARS-CoV-2 Delta and Omicron variants in subsets (30‒50 per arm). Participants recorded adverse events.

RESULTS

In 2-dose CoronaVac-primed adults prototype NAb geometric mean titers (GMT) were 203 IU/mL (95% confidence interval [CI], 182-227) and 939 IU/mL (95% CI, 841-1049) after CoronaVac and SCB-2019 boosters; the GMT ratio (4.63; 95% CI, 3.95-5.41) met predefined noninferiority and post-hoc superiority criteria. After 3-dose CoronaVac-priming prototype NAb GMTs were 279 IU/mL (95% CI, 240-325), 1044 IU/mL (95% CI, 898-1213), and 668 IU/mL (95% CI, 520-829) following CoronaVac, full and half-dose SCB-2019 boosters, respectively. NAb GMT ratios against Delta and Omicron comparing SCB-2019 with CoronaVac were all greater than 2. Mild to moderate reactogenicity was evenly balanced between groups. No vaccine-related serious adverse events were reported.

CONCLUSIONS

Full or half dose SCB-2019 boosters were well tolerated with superior immunogenicity than homologous CoronaVac, particularly against newly emerged variants. Clinical Trials Registration. NCT05188677.

摘要

背景

我们比较了在菲律宾，使用科兴新冠疫苗（CoronaVac）进行 2 或 3 剂接种的成年人中同源和异源加强免疫，以及使用重组蛋白疫苗 SCB-2019 进行异源加强免疫。

方法

CoronaVac 免疫的成年人（18-72 岁）接受同源或异源全或半剂量的 SCB-2019 加强免疫。我们在第 15 天评估了所有针对原型 SARS-CoV-2 的中和抗体（NAb）反应，并在亚组（每组 30-50 人）中评估了针对 SARS-CoV-2 Delta 和 Omicron 变体的 NAb。参与者记录了不良反应。

结果

在 2 剂 CoronaVac 免疫的成年人中，原型 NAb 的几何平均滴度（GMT）分别为接种 CoronaVac 和 SCB-2019 加强免疫后的 203 IU/mL（95%置信区间[CI]，182-227）和 939 IU/mL（95% CI，841-1049）；GMT 比值（4.63；95% CI，3.95-5.41）符合预先设定的非劣效性和事后优越性标准。在 3 剂 CoronaVac 免疫的成年人中，原型 NAb 的 GMT 分别为接种 CoronaVac、全剂量和半剂量 SCB-2019 加强免疫后的 279 IU/mL（95% CI，240-325）、1044 IU/mL（95% CI，898-1213）和 668 IU/mL（95% CI，520-829）。与 CoronaVac 相比，针对 Delta 和 Omicron 的 SCB-2019 的 NAb GMT 比值均大于 2。各组之间的轻度至中度不良反应发生率相当平衡。未报告与疫苗相关的严重不良事件。

结论

全剂量或半剂量的 SCB-2019 加强免疫具有良好的耐受性，其免疫原性优于同源的 CoronaVac，尤其是针对新出现的变体。

临床试验注册

NCT05188677。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d99d/10629704/b954ef118b76/jiad262f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d99d/10629704/13d755deb5be/jiad262f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d99d/10629704/17982669a387/jiad262f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d99d/10629704/d5f18e60027c/jiad262f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d99d/10629704/b954ef118b76/jiad262f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d99d/10629704/13d755deb5be/jiad262f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d99d/10629704/17982669a387/jiad262f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d99d/10629704/d5f18e60027c/jiad262f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d99d/10629704/b954ef118b76/jiad262f4.jpg

相似文献

1
Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults.异源 SCB-2019 疫苗对科兴疫苗 primed 成年人对奥密克戎 SARS-CoV-2 变异株中和滴度的增强作用优于同源加强针。
J Infect Dis. 2023 Nov 2;228(9):1253-1262. doi: 10.1093/infdis/jiad262.
2
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.SCB-2019 蛋白疫苗作为异源加强针，可提高对其他 COVID-19 疫苗接种后感染 SARS-CoV-2 奥密克戎变异株的中和抗体活性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2301632. doi: 10.1080/21645515.2023.2301632. Epub 2024 Jan 11.
3
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.在接种一剂灭活全病毒 COVID-19 疫苗（VLA2001）加强针后针对原始株、Delta 株和奥密克戎株变异病毒的安全性和免疫原性：COV-COMPARE 随机对照 3 期试验开放标签扩展的中期分析。
J Infect. 2023 Sep;87(3):242-254. doi: 10.1016/j.jinf.2023.06.022. Epub 2023 Jul 3.
4
Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.在健康成年人中，全剂量与半剂量的 COVID-19 疫苗（ChAdOx1-S 或 BNT162b2）或 CoronaVac 作为加强针接种后的免疫原性和安全性：在印度尼西亚进行的一项随机、观察者设盲、对照试验。
Lancet Infect Dis. 2023 May;23(5):545-555. doi: 10.1016/S1473-3099(22)00800-3. Epub 2023 Jan 11.
5
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.SCB-2019 是一种含佐剂的、重组新型冠状病毒刺突蛋白三聚体亚单位 COVID-19 疫苗，在健康的 12-17 岁青少年中的安全性和免疫原性。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2206359. doi: 10.1080/21645515.2023.2206359. Epub 2023 May 25.
6
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.在中国，两剂科兴新冠疫苗后接种一剂mRNA和三种平台型新冠疫苗作为第三剂的免疫原性、持久性和安全性：一项随机、双盲、安慰剂对照的2期试验。
EClinicalMedicine. 2022 Sep 28;54:101680. doi: 10.1016/j.eclinm.2022.101680. eCollection 2022 Dec.
7
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.接种科兴新冠疫苗、腺病毒载体新冠疫苗和辉瑞疫苗加强针后对 SARS-CoV-2 变异株的免疫原性和反应原性：一项在泰国健康成年人中开展的开放标签随机研究。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2091865. doi: 10.1080/21645515.2022.2091865. Epub 2022 Jul 11.
8
Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial.健康成年人中改良的奥密克戎适应灭活疫苗的安全性和免疫原性：一项随机、双盲、阳性对照的 III 期临床研究。
Front Immunol. 2023 Sep 18;14:1241153. doi: 10.3389/fimmu.2023.1241153. eCollection 2023.
9
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial.先前接种两剂科兴疫苗的个体中，经口服雾化 Ad5-nCoV 异源加强后抗体持久性和安全性：一项随机对照试验的 12 个月分析。
Emerg Microbes Infect. 2023 Dec;12(1):2155251. doi: 10.1080/22221751.2022.2155251.
10
The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.基于中国两项随机对照试验的18-59岁及60岁以上人群中异源康希诺生物新冠疫苗加强针加科兴新冠疫苗和同源科兴新冠疫苗接种的6个月抗体持久性研究
Vaccines (Basel). 2023 Dec 4;11(12):1815. doi: 10.3390/vaccines11121815.

引用本文的文献

1
Heterologous versus homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.成人异源与同源 COVID-19 加强疫苗接种：随机临床试验的系统评价和试验序贯分析。
BMC Med. 2024 Jun 24;22(1):263. doi: 10.1186/s12916-024-03471-3.
2
Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.不同 COVID-19 疫苗平台作为加强针的可互换性：一项模拟真实世界实践的 3 期研究。
Vaccine. 2024 Jul 25;42(19):3989-3998. doi: 10.1016/j.vaccine.2024.05.009. Epub 2024 May 17.
3

本文引用的文献

1
Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.两剂科兴疫苗接种后接种一剂或两剂 AZD1222 疫苗或 BNT162b2 信使 RNA 疫苗对德尔塔和奥密克戎变异株的免疫原性。
Int J Infect Dis. 2023 Apr;129:19-31. doi: 10.1016/j.ijid.2023.01.022. Epub 2023 Jan 20.
2
Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变种的新冠病毒原始毒株和加强针血清中和能力的系统评价
NPJ Vaccines. 2022 Nov 15;7(1):147. doi: 10.1038/s41541-022-00565-y.
3
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
SCB-2019 蛋白疫苗作为异源加强针，可提高对其他 COVID-19 疫苗接种后感染 SARS-CoV-2 奥密克戎变异株的中和抗体活性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2301632. doi: 10.1080/21645515.2023.2301632. Epub 2024 Jan 11.
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
在中国，两剂科兴新冠疫苗后接种一剂mRNA和三种平台型新冠疫苗作为第三剂的免疫原性、持久性和安全性：一项随机、双盲、安慰剂对照的2期试验。
EClinicalMedicine. 2022 Sep 28;54:101680. doi: 10.1016/j.eclinm.2022.101680. eCollection 2022 Dec.
4
A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19.一种异源 ChAdOx1 nCoV-19 和重组亚单位疫苗 MVC-COV1901 对 COVID-19 的随机对照试验。
Nat Commun. 2022 Sep 17;13(1):5466. doi: 10.1038/s41467-022-33146-7.
5
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis.异源加强免疫与同源加强免疫对 SARS-CoV-2 疫苗有效性和安全性的比较：系统评价和荟萃分析。
Int J Environ Res Public Health. 2022 Aug 29;19(17):10752. doi: 10.3390/ijerph191710752.
6
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis.新冠疫苗对现实世界中关注的 SARS-CoV-2 变异株的有效性：文献综述和荟萃分析。
Emerg Microbes Infect. 2022 Dec;11(1):2383-2392. doi: 10.1080/22221751.2022.2122582.
7
Duration of immunity following full vaccination against SARS-CoV-2: a systematic review.新型冠状病毒2019（SARS-CoV-2）全程接种疫苗后的免疫持续时间：一项系统综述
Arch Public Health. 2022 Sep 2;80(1):200. doi: 10.1186/s13690-022-00935-x.
8
Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study.Chadox1-S1-S新冠疫苗与SCB-2019候选疫苗的同源和异源加强免疫：一项随机、对照的2期研究。
Open Forum Infect Dis. 2022 Aug 16;9(8):ofac418. doi: 10.1093/ofid/ofac418. eCollection 2022 Aug.
9
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19.BNT162b2 加强免疫对 COVID-19 的异源或同源 ChAdOx1nCoV-19/BNT162b2 疫苗接种后 6 个月的免疫反应。
Nat Commun. 2022 Aug 18;13(1):4872. doi: 10.1038/s41467-022-32527-2.
10
Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.两剂 BNT162b2 疫苗对巴西和苏格兰青少年中 COVID-19 症状性和重症的有效性：时间依赖性的病例对照研究。
Lancet Infect Dis. 2022 Nov;22(11):1577-1586. doi: 10.1016/S1473-3099(22)00451-0. Epub 2022 Aug 8.